novartis

Alzheimer’s Treatment Granted FDA Approval

The U.S. FDA has granted Novartis Pharmaceuticals Corporation marketing clearance for Exelon (rivastigmine tartrate) capsules, a cholinesterase inhibitor for the treatment of mild to moderate Alzheimer’s disease. Exelon therapy is proven effective in multiple phase III trials in the three key domains used to assess the disease — global functioning (including activities of daily living Read more about Alzheimer’s Treatment Granted FDA Approval[…]

skye pharma

Skyepharma Plans Joint Development With Novartis

SkyePharma PLC announced an agreement with Novartis Pharma AG to jointly develop a new product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The product will combine Novartis’ novel long-acting bronchodilator QAB149 with two SkyePharma technologies SkyeHaler(TM), a breath-activated multi-dose dry powder inhaler (MDDPI) device, to be marketed by Novartis as the Read more about Skyepharma Plans Joint Development With Novartis[…]

novartis

Discovery Services Agreement For Novartis And Transgenomic

Transgenomic Inc. has entered into several specific agreements with Novartis Pharmaceuticals Corp. to provide mutation discovery services in the context of translational research programs in oncology. The goal is to support biomarker discovery efforts in the context of clinical trials by identifying genetic mutations that correlate with patients’ response(s) to cancer therapeutics. Transgenomic has performed Read more about Discovery Services Agreement For Novartis And Transgenomic[…]

novartis

Chiron Licenses Acute Rejection Agent From Novartis

Chiron has acquired exclusive worldwide development and commercialization rights to aerosolized cyclosporine (AcsA), an agent with potential in lung transplant acute rejection from Novartis. Clinical studies have been conducted in about 100 lung transplant patients at the University of Pittsburgh. Terms of agreement were not disclosed. Chiron Corporation, headquartered in Emeryville, California, has a strategic Read more about Chiron Licenses Acute Rejection Agent From Novartis[…]

Acquire Dragon Pharma Labs on the Internet

EQ 300

Injectable Anabolic Steroid
Principal Ingredient: Boldenone Undecylenate
Manufacturer: Dragon Pharmaceuticals
Amount: 1 X 10 ml (300 mg/ml)

NPP 150

Injectable Anabolic Steroid
Basal Chemical Name: Nandrolone Phenylpropionate
Manufacturer: Dragon Pharma LLC
Pack: 1 X 10 ml (150 mg/ml)

Clenbuterol - Discount Price

Administration: Oral
Prime Substance: Clenbuterol Hydrochloride
Made by: Dragon Pharmaceuticals
Package: 30 x 100 tablets (40 mcg/pill)
Price: 30 x $20

Trenbolone 200 [10 Vials]

Injectable Steroid for Muscle Growth
Main Substance: Trenbolone Enanthate
Made by: Dragon Pharmaceuticals
10 Vials [10 mL per Vial (200 mg/ml)]
Price: 10 x $77.00 = $770.00 in Total

Masteron 200

Injectable Steroid for Muscle Growth
Principal Chemical Name: Drostanolone Enanthate
Made by: Dragon Pharmaceutical
10 mL Sterile Multi-dose Vial (200 mg/mL)

Parabolan 100 [10 Vials]

Injectable Steroid for Muscle Growth
Basic Substance: Trenbolone Hexahydrobenzylcarbonate
Producer: Dragon Pharmaceutical
10 Vials [10 mL per Vial (100 mg/ml)]
Price: 10 x $69.00 = $690.00 in Total

Enantat 250

Prime Component: Testosterone Enanthate
Produced by: Dragon Pharma LLC
Package: 10 x 10 mL vial (250 mg/mL)

Trenbolone 100

Basal Constituent: Trenbolone Acetate
Manufacturer: Dragon Pharma Labs
Pack: 10 mL vial (100 mg/mL)

Deca 300

Base Chemical Name: Nandrolone Decanoate
Branded by: Dragon Pharma
Unit: 10 x 10 mL vial (300 mg/mL)

Anavar

Active Ingredient: Oxandrolone
Producer: Dragon Pharma
Unit: 100 tabs (50 mg/pill)

Enantat 400

Basic Component: Testosterone Enanthate
Made by: Dragon Pharmaceuticals
Amount: 10 mL vial (400 mg/mL)

Suspension 100

Base Ingredient: Testosterone Suspension
Branded by: Dragon Pharmaceutical
Pack: 10 mL vial (100 mg/mL)